Select a medication above to begin.
Cablivi (caplacizumab-yhdp)
caplacizumab
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = caplacizumab-yhdp
thrombotic thrombocytopenic purpura, acquired
- [11 mg IV x1 at least 15 min prior to 1st plasma exchange, then 11 mg SC qd after daily plasma exchange starting day 1 until 30 days after last daily plasma exchange]
- Info: use with immunosuppressive therapy; may extend tx for up to 28 additional days if persistent disease; D/C if more than 2 disease recurrences during tx; D/C 7 days before elective surgery, dental procedures, or other invasive interventions
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- mild-moderate impairment: not defined; severe impairment: not defined, caution advised
Peds Dosing .
- Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = caplacizumab-yhdp
thrombotic thrombocytopenic purpura, acquired
- [12 yo and older]
- Dose: 11 mg IV x1 at least 15 min prior to 1st plasma exchange, then 11 mg SC qd after daily plasma exchange starting day 1 until 30 days after last daily plasma exchange; Info: use with immunosuppressive therapy; may extend tx for up to 28 additional days if persistent disease; D/C if more than 2 disease recurrences during tx; D/C 7 days before elective surgery, dental procedures, or other invasive interventions
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- mild-moderate impairment: not defined; severe impairment: not defined, caution advised
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- avoid: tx x7 days before elective surgery
- avoid: tx x7 days before invasive procedure
- caution: hepatic impairment, severe
- caution: coagulation disorder
- caution: hemophilia
Drug Interactions .
Overview
caplacizumab
von Willebrand factor (vWF)-directed antibody
- antiplatelet
Contraindicated
- abrocitinib
Avoid/Use Alternative
- alteplase
- anagrelide
- antithrombin
- apixaban
- argatroban
- aspirin
- bivalirudin
- cangrelor
- cilostazol
- clopidogrel
- collagenase clostridium histolyticum
- dabigatran
- dalteparin
- danshen
- defibrotide
- dipyridamole
- edoxaban
- enoxaparin
- eptifibatide
- fondaparinux
- heparin
- ibritumomab tiuxetan
- prasugrel
- reteplase
- rivaroxaban
- tenecteplase
- ticagrelor
- tirofiban
- vorapaxar
- warfarin
Monitor/Modify Tx
- acalabrutinib
- ado-trastuzumab emtansine
- afatinib
- alpha-tocopherol (vitamin E)
- anacaulase topical
- asparaginase
- avapritinib
- axitinib
- bevacizumab
- binimetinib
- brentuximab vedotin
- bromelain
- bromfenac ophthalmic
- cabazitaxel
- cabozantinib
- calaspargase
- carfilzomib
- celecoxib
- citalopram
- cysteamine
- dasatinib
- deferasirox
- desvenlafaxine
- deuruxolitinib
- diclofenac
- diclofenac ophthalmic
- diclofenac topical
- diflunisal
- dimethyl fumarate
- diosmin
- diroximel fumarate
- donanemab
- duloxetine
- encorafenib
- epoprostenol
- erlotinib
- escitalopram
- ethanol
- etodolac
- evening primrose oil
- fenoprofen
- fenugreek
- fluoxetine
- flurbiprofen
- flurbiprofen ophthalmic
- fluvoxamine
- fruquintinib
- garlic
- gefitinib
- gemtuzumab ozogamicin
- ginkgo
- hydrocortisone
- ibrutinib
- ibuprofen
- ibuprofen lysine
- icosapent ethyl
- iloprost inhaled
- imatinib
- indomethacin
- ketoprofen
- ketorolac
- ketorolac ophthalmic
- lecanemab
- lenvatinib
- levomilnacipran
- lifileucel
- magnesium salicylate
- meclofenamate
- mefenamic acid
- meloxicam
- methotrexate
- methyl salicylate topical
- milnacipran
- mitotane
- monomethyl fumarate
- mycophenolate mofetil
- mycophenolic acid
- nabumetone
- naproxen
- nattokinase
- nepafenac ophthalmic
- niacin (vitamin B3)
- nilotinib
- nintedanib
- nusinersen
- obinutuzumab
- omega-3-acid
- oxaliplatin
- oxaprozin
- pacritinib
- paroxetine
- pazopanib
- pegaspargase
- penicillin G
- pentosan polysulfate sodium
- pentoxifylline
- piperacillin
- piroxicam
- pirtobrutinib
- plasminogen, human
- ponatinib
- porfimer
- pralsetinib
- ramucirumab
- ranibizumab
- regorafenib
- remibrutinib
- resveratrol
- revakinagene taroretcel
- salsalate
- saw palmetto
- selpercatinib
- selumetinib
- sepiapterin
- sertraline
- sirolimus albumin-bound
- sorafenib
- sotatercept
- sugammadex
- sulindac
- sunitinib
- temsirolimus
- tipranavir
- tisotumab vedotin
- tivozanib
- tolmetin
- tovorafenib
- trametinib
- trazodone
- treprostinil
- upadacitinib
- vadadustat
- valproic acid
- vandetanib
- venlafaxine
- vilazodone
- vinpocetine
- vortioxetine
- willow bark
- zanubrutinib
- ziv-aflibercept
Adverse Reactions .
Serious Reactions
- bleeding
- hemorrhage
- hematuria
- dyspnea
Common Reactions
- epistaxis
- headache
- gingival bleeding
- fatigue
- urticaria
- fever
- paresthesia
- dyspnea
- back pain
- injection site hemorrhage
- myalgia
- UTI
- vaginal hemorrhage
- rectal hemorrhage
- hematuria
- heavy menstrual bleeding
- hematoma
- injection site reaction
- tachycardia
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
benefits outweigh risks during pregnancy; no human data available; no known risk of fetal harm based on animal data at 30x systemic exposure; risk of hemorrhage in fetuses, neonates, and pregnant patients based on drug's mechanism of action
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for caplacizumab: proteolytic degradation; CYP450: unknown
Excretion: for caplacizumab: urine; Half-life: variable; Info: half-life dependent on target von Willebrand factor levels
Subclass: Antiplatelets, Hematologic
Mechanism of Action
for caplacizumab: binds to the A1-domain of von Willebrand factor, inhibiting interaction with platelets, thereby reducing platelet adhesion and consumption
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.